This approach prioritized multiple BrCa candidate genes that resembled I-O therapeutics, such as LSP1 and TLR1, which were orthogonally validated by human BrCa disease association and comparative modeling, respectively. The gene discussed is LSP1; the disease is invasive breast carcinoma.